

MEDICAID PHARMACY PRIOR AUTHORIZATION ADVISORY COMMITTEE
Recommendations Summary
February 10, 2010

In Attendance:

	Committee Member	Yes or No
1	Rosanne Barber	No
2	Catherine Decker PharmD	Yes
3	Bradley Fedderly M.D.	Yes, via phone
4	Lawrence Fleming M.D.	Yes
5	Al Liegel, RPh	Yes
6	Kevin Izard M.D.	No
7	Steve Maike RPh	Yes
8	Pat Towers	Yes
9	Alicia Walker PharmD	Yes, via phone
10	Michael Witkovsky M.D.	Yes
11	James Boblin M.D.	Yes
12	Ward Brown, M.D.	Yes
13	Anthony DeFranco M.D., FACC	No
14	Ronald Diamond, M.D.	Yes

Drug Classes for Review

FIBROMYALGIA (Fibromyalgia)
ANTICONVULSANTS (Seizure Disorders)
SEDATIVE HYPNOTICS (Insomnia)
ANALGESICS, NARCOTIC, LONG ACTING (Pain)
ANALGESICS, NARCOTIC, SHORT ACTING (Pain)
ANTIMIGRAINE AGENTS, TRIPTANS (Migraine Headaches)
SKELETAL MUSCLE RELAXANTS (Spasticity and Muscle Relaxants)
ANGIOTENSIN MODULATORS (High Blood Pressure)
ANGIOTENSIN MODULATORS COMBINATIONS (High Blood Pressure)
BETA BLOCKERS (High Blood Pressure and Heart Failure)
CALCIUM CHANNEL BLOCKERS (High Blood Pressure)
LIPOTROPICS, OTHER (High Cholesterol)
LIPOTROPICS, STATINS (High Cholesterol)
ULCERATIVE COLITIS AGENTS (Inflammation and Sores of the Intestine)
ANTIBIOTICS, GI (GI Infections)
PROTON PUMP INHIBITORS (Ulcers and Reflux)
ACNE AGENTS, TOPICAL (Acne)
IMPETIGO AGENTS, TOPICAL (Impetigo)
ANTICOAGULANTS, INJECTABLE (Clot Prevention)
ERYTHROPOEISIS STIMULATING PROTEINS (Treatment of Low Blood Levels)
GROWTH HORMONE (Growth Deficiency)
HEPATITIS C AGENTS (Hepatitis C)
MULTIPLE SCLEROSIS AGENTS (Multiple Sclerosis)
BLADDER RELAXANTS PREPARATIONS (Overactive Bladder)
BPH TREATMENTS (Enlargement of the Prostate)
HYPOGLYCEMICS, MEGLITINIDES (Type 2 Diabetes)
HYPOGLYCEMICS, TZD (Type 2 Diabetes)
PHOSPHATE BINDERS (Removal of Phosphates in Kidney Disease)
ANTIHISTAMINES, MINIMALLY SEDATING (Allergies)
OTIC ANTIBIOTICS (Ear Infections)
PAH AGENTS (Pulmonary Arterial Hypertension)
COUGH AND COLD, NARCOTICS (Cough and Cold)

1. FIBROMYALGIA (Fibromyalgia)						
Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	State Modifications	Secretary Modifications
SAVELLA (ORAL)	2.4%	NR	YES			
LYRICA (ORAL)	51.7%	NR	NO	YES		
CYMBALTA (ORAL)	45.9%	NR	NO			

- Discussion: Dr. Boblin wondered how many Lyrica prescriptions were being used for fibromyalgia. There was also concern raised about including diagnoses on prescription orders.
- The Committee made a motion to accept staff recommendations, but add Lyrica as a preferred agent. They also recommended no diagnosis or prior authorization restrictions for Lyrica.
 - Motion – James Boblin
 - Second – Brad Fedderly
 - The vote was 7-4 in favor of the motion.

2. ANTICONVULSANTS (Seizure Disorders)						
Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	State Modifications	Secretary Modifications
PHENOBARBITAL (ORAL)	3.4%	ON	Yes-Generic			
CLONAZEPAM (ORAL)	29.9%	ON	Yes-Generic			
TOPIRAMATE TABLETS (ORAL)	6.9%	ON	Yes-Generic			
CARBAMAZEPINE (ORAL)	2.7%	ON	Yes-Generic			
GABAPENTIN (ORAL)	16.8%	ON	Yes-Generic			
CELONTIN (ORAL)	0.00%	ON	Yes			
DIVALPROEX (ORAL)	4.1%	ON	Yes-Generic			
LAMOTRIGINE (ORAL)	12.5%	ON	Yes-Generic			
VALPROIC ACID (ORAL)	0.9%	ON	Yes-Generic			
PRIMIDONE (ORAL)	0.9%	ON	Yes-Generic			
PHENYTOIN (ORAL)	2.5%	ON	Yes-Generic			
DILANTIN INFATAB (ORAL)	0.4%	NR	Yes			
CARBATROL (ORAL)	1.1%	ON	Yes			
PHENYTEK (ORAL)	0.00%	OFF	No			
LEVETIRACETAM SOLUTION (ORAL)	1.00%	ON	Yes-Generic			
PEGANONE (ORAL)	0.00%	ON	Yes			
LEVETIRACETAM TABLETS (ORAL)	3.5%	ON	Yes-Generic			
MEPHOBARBITAL (ORAL)	0.00%	ON	Yes-Generic			
OXCARBAZEPINE TABLETS (ORAL)	2.1%	ON	Yes-Generic			

2. ANTICONVULSANTS (Seizure Disorders)

Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	State Modifications	Secretary Modifications
ETHOSUXIMIDE (ORAL)	0.2%	ON	Yes-Generic			
GABITRIL (ORAL)	0.1%	ON	Yes			
EQUETRO (ORAL)	0.00%	ON	Yes			
CARBAMAZEPINE XR (ORAL)	0.2%	OFF	No-Generic			
FELBATOL (ORAL)	0.5%	ON	Yes			
STAVZOR (ORAL)	0.00%	OFF	No			
DIVALPROEX ER (ORAL)	5.4%	ON	Yes-Generic			
LAMICTAL ODT (ORAL)	0.00%	NR	No			
DIVALPROEX SPRINKLE (ORAL)	1.4%	ON	Yes-Generic			
KEPPRA XR (ORAL)	0.2%	ON	Yes			
OXCAEBAZEPINE SUSPENSION	0.4%	ON	Yes			
LAMICTAL XR (ORAL)	0.00%	NR	No			
DIASTAT (RECTAL)	0.7%	ON	Yes			
TOPIRAMATE SPRINKLE (ORAL)	0.2%	ON	Yes-Generic			
VIMPAT (ORAL)	0.1%	NR	No			
BANZEL (ORAL)	0.2%	NR	No			
SABRIL (ORAL)	0.00%	NR	No			

- The Committee made a motion to accept staff recommendations.
 - Motion – Pat Towers
 - Second – Ward Brown
 - All members were in favor of the motion.

3. SEDATIVE HYPNOTICS (Insomnia)

Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	State Modifications	Secretary Modifications
ZOLPIDEM (ORAL)	62.9%	ON	Yes-Generic			
FLURAZEPAM (ORAL)	1.4%	ON	Yes-Generic	No		
DORAL (ORAL)	0.00%	OFF	No			
TRIAZOLAM (ORAL)	1.00%	OFF	No-Generic			
TEMAZEPAM (ORAL)	22.5%	ON	Yes-Generic			
ESTAZOLAM (ORAL)	0.6%	ON	Yes-Generic			
ZALEPLON (ORAL)	0.4%	ON	Yes-Generic			
CHLORAL HYDRATE (ORAL)	0.3%	ON	Yes-Generic			
EDLUAR (SUBLINGUAL)	0.00%	NR	No			
ROZEREM (ORAL)	2.9%	ON	Yes			

3. SEDATIVE HYPNOTICS (Insomnia)						
Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	State Modifications	Secretary Modifications
AMBIEN CR (ORAL)	4.5%	OFF	No			
LUNESTA (ORAL)	3.5%	OFF	No			

- Discussion: Due to the safety issues regarding the long half-life of flurazepam and the “hangover” effect, the Mental Health Drug Advisors provided comment that this drug should be recommended as non-preferred. The PA Committee agreed.
- The Committee made a motion to accept staff recommendations, but make flurazepam a non-preferred agent.
 - Motion – James Boblin
 - Second – Brad Fedderly
 - All members were in favor of the motion.

4. ANALGESICS, NARCOTIC, LONG ACTING (Pain)						
Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	State Modifications	Secretary Modifications
METHADONE (ORAL)	19.4%	ON	YES-GENERIC			
MORPHINE ER (ORAL)	23.5%	ON	YES-GENERIC			
KADIAN (ORAL)	4.2%	ON	YES			
OPANA ER (ORAL)	0.5%	OFF	NO			
RYZOLT (ORAL)	0.1%	NR	NO			
TRAMADOL ER (ORAL)	0.7%	OFF	NO-GENERIC			
FENTANYL (TRANSDERM)	4.0%	ON	YES-GENERIC			
OXYCONTIN (ORAL)	31.1%	ON	YES			
AVINZA (ORAL)	0.2%	OFF	NO			
EMBEDA (ORAL)	0.0%	NR	NO			
OXYCODONE ER (ORAL)	1.3%	OFF	NO-GENERIC			
DURAGESIC MATRIX (TRANSDERM.)	15.0%	ON	NO			

- The Committee made a motion to accept staff recommendations.
 - Motion – Lawrence Fleming
 - Second – Michael Witkovsky
 - All members were in favor of the motion.

5. ANALGESICS, NARCOTIC, SHORT ACTING (Pain)						
Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	State Modifications	Secretary Modifications
APAP/CODEINE (ORAL)	8.8%	ON	YES-GENERIC			
TRAMADOL (ORAL)	11.6%	ON	YES-GENERIC			
HYDROCODONE/ APAP (ORAL)	48.1%	ON	YES-GENERIC			
PROPOXYPHENE/APAP (ORAL)	4.9%	ON	NO-GENERIC			
ASA/CODEINE (ORAL)	0.0%	ON	YES-GENERIC			
MORPHINE IR (ORAL)	0.8%	ON	YES-GENERIC			
OXYCODONE/APAP (ORAL)	18.2%	ON	YES-GENERIC			
PROPOXYPHENE (ORAL)	0.2%	ON	NO-GENERIC			
HYDROMOPHONE (ORAL)	0.6%	ON	YES-GENERIC			
PENTAZOCINE/NALOXONE (ORAL)	0.0%	OFF	NO-GENERIC			
HYDROCODONE/IBUPROFEN (ORAL)	0.4%	ON	YES-GENERIC			
PENTAZOCINE/APAP	0.0%	OFF	NO-GENERIC			
MEPERIDINE (ORAL)	0.0%	OFF	NO-GENERIC			
TRAMADOL/APAP (ORAL)	0.1%	OFF	NO-GENERIC			
PANLOR DC (ORAL)	0.0%	OFF	NO			
OXYCODONE (ORAL)	6.0%	ON	YES-GENERIC			
CODEINE (ORAL)	0.1%	ON	YES-GENERIC			
OXYCODONE/IBUPROFEN (ORAL)	0.0%	ON	YES-GENERIC			
IBUDONE (ORAL)	0.0%	OFF	NO			
OXYCODONE/ASA (ORAL)	0.0%	ON	YES-GENERIC			
REPREXAIN (ORAL)	0.0%	NR	NO			
DIHYDROCODEINE/APAP/CAFFEINE (ORAL)	0.0%	ON	NO-GENERIC			
ZAMICET (ORAL)	0.0%	OFF	NO			
DILAUDID LIQUID (ORAL)	0.0%	NR	NO			
LEVORPHANOL (ORAL)	0.0%	OFF	NO-GENERIC			
NUCYNTA (ORAL)	0.0%	NR	NO			
OPANA (ORAL)	0.1%	OFF	NO			
FENTANYL (BUCCAL)	0.0%	OFF	NO-GENERIC			
FENTORA (BUCCAL)	0.0%	OFF	NO			
ONSOLIS (BUCCAL)	0.0%	NR	NO			

- Discussion: Members of the committee suggested that letters be sent to prescribers of propoxyphene and propoxyphene with acetaminophen to ensure they were aware the drug would be non-preferred.

- The Committee made a motion to accept staff recommendations, mail letters to physicians prescribing propoxyphene and propoxyphene with acetaminophen, and delay the implementation of this change until 7/1/10.
 - Motion – Brad Fedderly
 - Second – James Boblin
 - The vote was 10-1 in favor of the motion.

6. ANTIMIGRAINE AGENTS, TRIPTANS (Migraine Headaches)						
Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	State Modifications	Secretary Modifications
SUMATRIPTAN (ORAL)	50.3%	ON	Yes-Generic			
BUTALBITALCOMPOUND (ORAL)	0.4%	OFF	No-Generic			
BUTALBITAL COMPOUND W/ CODEINE (ORAL)	2.00%	OFF	No-Generic			
MAXALT/MLT (ORAL)	22.7%	ON	Yes			
TREXIMET (ORAL)	1.1%	OFF	No			
AXERT (ORAL)	0.6%	OFF	No			
FROVA (ORAL)	0.9%	OFF	No			
RELPAX (ORAL)	10.1%	ON	No			
ZOMIG/ZOMIG ZMT (ORAL)	2.00%	OFF	No			
ZOMIG (NASAL)	0.3%	OFF	No			
AMERGE (ORAL)	0.8%	OFF	No			
SUMATRIPTAN (NASAL)	2.2%	ON	Yes-Generic			
SUMATRIPTAN (SUBCUTANE)	6.7%	ON	YES-Generic			

- The Committee made a motion to accept staff recommendations.
 - Motion – James Boblin
 - Second – Ward Brown
 - All members were in favor of the motion.

7. SKELETAL MUSCLE RELAXANTS (Spasticity and Muscle Relaxants)						
Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	State Modifications	Secretary Modifications
CYCLOBENZAPRINE (ORAL)	65.4%	ON	Yes-Generic			
CHLORZOXAZONE (ORAL)	0.9%	ON	Yes-Generic			
BACLOFEN (ORAL)	12.7%	ON	Yes-Generic			
CARISOPRODOL (ORAL)	3.4%	OFF	No-Generic			
METHOCARBAMOL (ORAL)	6.1%	ON	Yes-Generic			

7. SKELETAL MUSCLE RELAXANTS (Spasticity and Muscle Relaxants)						
Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	State Modifications	Secretary Modifications
TIZANIDINE (ORAL)	9.1%	ON	Yes-Generic			
CARISOPRODOL COMPOUND (ORAL)	0.00%	OFF	No-Generic			
SOMA 250MG (ORAL)	0.1%	OFF	No			
ORPHENADRINE (ORAL)	0.3%	OFF	No-Generic			
ORPHENADRINE COMPOUND (ORAL)	0.1%	OFF	No-Generic			
SKELAXIN (ORAL)	1.3%	OFF	No			
DANTROLENE SODIUM (ORAL)	0.6%	ON	Yes-Generic			
FEXIMID (ORAL)	0.0%	OFF	No			
ZANAFLEX CAPSULES (ORAL)	0.1%	OFF	No			
AMRIX (ORAL)	0.1%	OFF	No			

- The Committee made a motion to accept staff recommendations.
 - Motion – Michael Witkovsky
 - Second – Catherine Decker
 - All members were in favor of the motion.

8. ANGIOTENSIN MODULATORS (High Blood Pressure)						
Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	State Modifications	Secretary Modifications
CAPTOPRIL/HCTZ (ORAL)	1.00%	ON	Yes-Generic			
ENALAPRIL/HCTZ (ORAL)	8.6%	ON	Yes-Generic			
RAMIPRIL (ORAL)	0.5%	ON	Yes-Generic			
LISINOPRIL/HCTZ (ORAL)	49.4%	ON	Yes-Generic			
BENAZEPRIL/HCTZ (ORAL)	5.2%	ON	Yes-Generic			
QUINAPRIL/HCTZ (ORAL)	0.6%	ON	Yes-Generic			
FOSINOPRIL/HCTZ (ORAL)	1.2%	ON	Yes-Generic			
PERINDOPRIL (ORAL)	0.00%	OFF	Yes-Generic			
MICARDIS/MICARDIS HCT (ORAL)	1.5%	ON	Yes			
TRANDOLAPRIL (ORAL)	0.1%	OFF	Yes-Generic			
COZAAR/HYZAAR (ORAL)	9.6%	ON	Yes			
DIOVAN/HCT (ORAL)	14.6%	ON	Yes			
AVAPRO/AVALIDE (ORAL)	2.6%	ON	No			
MOEXIPRIL/HCTZ (ORAL)	0.1%	OFF	No-Generic			

8. ANGIOTENSIN MODULATORS (High Blood Pressure)						
Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	State Modifications	Secretary Modifications
BENICAR/BENICAR HCT (ORAL)	4.3%	ON	No			
TEKTRNA/TEKTRNA HCT (ORAL)	0.2%	OFF	No			
ATACAND/ATACAND HCT (ORAL)	0.4%	OFF	No			
TEVETEN/TEVETEN HCT (ORAL)	0.00%	OFF	No			

- The Committee made a motion to accept staff recommendations.
 - Motion – Pat Towers
 - Second – Ward Brown
 - All members were in favor of the motion.

9. ANGIOTENSIN MODULATORS COMBINATIONS (High Blood Pressure)						
Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	State Modifications	Secretary Modifications
EXFORGE/EXFORGE HCT (ORAL)	42.8%	ON	Yes			
AZOR (ORAL)	23.1%	ON	Yes			
VALTURNA (ORAL)	0.00%	NR	Yes			
TARKA (ORAL)	5.7%	ON	Yes			
AMLODIPINE/BENAZEPRIL (ORAL)	28.4%	OFF	No-Generic			
TWYNSTA (ORAL)	0.00%	NR	No			

- The Committee made a motion to accept staff recommendations.
 - Motion – Lawrence Fleming
 - Second – Al Liegel
 - All members were in favor of the motion.

10. BETA BLOCKERS (High Blood Pressure and Heart Failure)

Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	State Modifications	Secretary Modifications
ATENOLOL/CHLORTHALIDONE (ORAL)	28.3%	ON	Yes-Generic			
METOPROLOL/HCTZ (ORAL)	28.7%	ON	Yes-Generic			
CARVEDILOL (ORAL)	10.2%	ON	Yes-Generic			
PINDOLOL (ORAL)	0.1%	ON	Yes-Generic			
NADOLOL/BENDROFLUMETHIAZIDE (ORAL)	1.1%	ON	Yes-Generic			
SOTALOL (ORAL)	0.9%	ON	Yes-Generic			
ACEBUTOLOL (ORAL)	0.2%	ON	Yes-Generic			
INNOPRAN XL (ORAL)	0.0%	OFF	Yes			
LABETALOL (ORAL)	2.4%	ON	Yes-Generic			
BISOPROLOL/HCTZ (ORAL)	1.4%	ON	Yes-Generic			
TIMOLOL (ORAL)	0.00%	ON	Yes-Generic			
PROPRANOLOL/HCTZ (ORAL)	6.8%	ON	Yes-Generic			
LEVATOL (ORAL)	0.00%	OFF	No			
BYSTOLIC (ORAL)	0.6%	OFF	No			
METOPROLOL XL (ORAL)	18.3%	ON	Yes-Generic			
COREG CR (ORAL)	0.2%	OFF	No			
BETAXOLOL (ORAL)	0.00%	OFF	No-Generic			

- The Committee made a motion to accept staff recommendations.
 - Motion – Al Liegel
 - Second – Ward Brown
 - All members were in favor of the motion.

11. CALCIUM CHANNEL BLOCKERS (High Blood Pressure)

Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	State Modifications	Secretary Modifications
AMLODIPINE (ORAL)	62.1%	ON	Yes-Generic			
NICARDIPINE (ORAL)	0.10%	ON	Yes-Generic			
VERAPAMIL (ORAL)	8.0%	ON	Yes-Generic			
DYNACIRC CR (ORAL)	0.1%	ON	Yes			
CARDIZEM LA (ORAL)	0.2%	OFF	No			
DILTIAZEM (ORAL)	19.4%	ON	Yes-Generic			
ISRADIPINE (ORAL)	0.1%	OFF	No-Generic			
COVERA-HS (ORAL)	0.00%	OFF	No			
NIFEDIPINE IR (ORAL)	0.4%	ON	Yes-Generic			

11. CALCIUM CHANNEL BLOCKERS (High Blood Pressure)

Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	State Modifications	Secretary Modifications
NIFEDIPINE ER (ORAL)	7.5%	ON	Yes-Generic			
FELODIPINE ER (ORAL)	1.7%	ON	Yes-Generic			
VERAPAMIL ER PM (ORAL)	0.2%	ON	Yes-Generic			
SULAR (ORAL)	0.2%	OFF	No			
NISOLDIPINE (ORAL)	0.1%	OFF	No-Generic			
CARDENE SR (ORAL)	0.00%	OFF	No			
NIMODIPINE (ORAL)	0.00%	ON	Yes-Generic			

- The Committee made a motion to accept staff recommendations.
 - Motion – James Boblin
 - Second – Catherine Decker
 - All members were in favor of the motion.

12. LIPOTROPICS, OTHER (High Cholesterol)

Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	State Modifications	Secretary Modifications
NIACOR (ORAL)	0.0%	ON	YES			
GEMFIBROZIL (ORAL)	23.9%	ON	YES-GENERIC			
LIPOFEN (ORAL)	0.0%	OFF	NO			
ANTARA (ORAL)	0.1%	OFF	YES			
TRILIPIX (ORAL)	0.3%	NR	YES			
TRICOR (ORAL)	17.8%	ON	YES			
NIASPAN (ORAL)	19.8%	ON	YES			
COLESTIPOL (ORAL)	1.1%	ON	YES-GENERIC			
CHOLESTYRAMINE (ORAL)	4.0%	ON	YES-GENERIC			
ZETIA (ORAL)	19.0%	ON	NO			
FENOFIBRIC ACID (ORAL)	0.0%	OFF	NO-GENERIC			
FENOFIBRATE (ORAL)	9.6%	ON	YES-GENERIC			
FENOGLIDE (ORAL)	0.0%	OFF	NO			
LOVAZA (ORAL)	3.2%	ON	YES			
WELCHOL (ORAL)	1.2%	OFF	NO			
FIBRICOR (ORAL)	0.0%	NR	NO			
TRIGLIDE (ORAL)	0.0%	OFF	NO			

- The Committee made a motion to accept staff recommendations.
 - Motion – Lawrence Fleming
 - Second – Michael Witkovsky
 - All members were in favor of the motion.

13. LIPOTROPICS, STATINS (High Cholesterol)						
Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	State Modifications	Secretary Modifications
SIMVASTATIN (ORAL)	50.8%	ON	Yes-Generic			
PRAVASTATIN (ORAL)	5.4%	ON	Yes-Generic			
LOVASTATIN (ORAL)	11.5%	ON	Yes-Generic			
LESCOL/LESCOL XL (ORAL)	1.8%	ON	Yes			
CRESTOR (ORAL)	3.4%	OFF	No			
SIMCOR (ORAL)	0.2%	ON	Yes			
VYTORIN (ORAL)	9.1%	ON	Yes			
LIPITOR (ORAL)	17.4%	ON	Yes			
CADUET (ORAL)	0.2%	ON	No			
ALTOPREV (ORAL)	0.00%	OFF	No			
ADVICOR (ORAL)	0.1%	OFF	No			

- The Committee made a motion to accept staff recommendations.
 - Motion – Ron Diamond
 - Second – Al Liegel
 - All members were in favor of the motion.

14. ULCERATIVE COLITIS AGENTS (Inflammation and Sores of the Intestine)						
Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	State Modifications	Secretary Modifications
SULFASALAZINE (ORAL)	30.5%	ON	Yes-Generic			
APRISO (ORAL)	0.00%	NR	Yes			
DIPENTUM (ORAL)	0.2%	OFF	No			
ASACOL (ORAL)	53.6%	ON	Yes			
PENTASA (ORAL)	7.6%	OFF	No			
BALSALAZIDE (ORAL)	2.0%	ON	Yes-Generic			
CANASA (RECTAL)	2.4%	ON	Yes			
LIALDA (ORAL)	2.0%	OFF	No			
MESALAMINE (RECTAL)	1.5%	ON	No-Generic			
SF-ROWASA (RECTAL)	0.00%	NR	No			

- The Committee made a motion to accept staff recommendations.
 - Motion – Ron Diamond
 - Second – Lawrence Fleming
 - All members were in favor of the motion.

15. ANTIBIOTICS, GI (GI Infections)						
Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	State Modifications	Secretary Modifications
METRONIDAZOLE (ORAL)	91.6%	ON	YES-GENERIC			
NEOMYCIN (ORAL)	0.9%	ON	YES-GENERIC			
TINDAMAX (ORAL)	4.9%	ON	YES			
FLAGYL ER (ORAL)	0.0%	OFF	NO			
ALINIA (ORAL)	0.6%	ON	YES			
XIFAXAN (ORAL)	0.9%	OFF	NO			
VANCOGIN HCL (ORAL)	1.2%	ON	YES			

- The Committee made a motion to accept staff recommendations.
 - Motion – Catherine Decker
 - Second – Ward Brown
 - All members were in favor of the motion.

16. PROTON PUMP INHIBITORS (Ulcers and Reflux)						
Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	State Modifications	Secretary Modifications
ACIPHEX (ORAL)	1.6%	ON	Yes			
OMEPRAZOLE (ORAL)	40.9%	ON	Yes-Generic			
KAPIDEX (ORAL)	0.00%	NR	No			
NEXIUM (ORAL)	6.8%	OFF	No			
PROTONIX SUSP (ORAL)	0.00%	NR	No			
LANSOPRAZOLE (ORAL)	0.00%	ON	No-Generic			
PREVACID SOLUTAB (ORAL)	4.8%	OFF	No			
NEXIUM SUSPENSION (ORAL)	0.00%	OFF	No			
PANTOPRAZOLE (ORAL)	2.7%	OFF	No-Generic			
PRILOSEC SUSP (ORAL)	0.00%	NR	No			

- Discussion: Alicia Walker indicated that providers were compounding Prilosec Suspension. Medicaid policy does not allow providers to compound a product that is commercially available. Jason Helgerson discussed making Aciphex as the only preferred agent in the class.

- The Committee made a motion to accept staff recommendations.
 - Motion – James Boblin
 - Second – Michael Witkovsky
 - All members were in favor of the motion.

17. ACNE AGENTS, TOPICAL (Acne)						
Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	State Modifications	Secretary Modifications
CLINAC BPO (Topical)	0.2%	ON	YES			
AZELEX (Topical)	1.7%	ON	YES			
ERYTHROMYCIN (Topical)	5.8%	ON	YES-GENERIC			
BENZOYL PEROXIDE (Topical)	24.3%	ON	YES-GENERIC			
CLINDAMYCIN PHOSPHATE (Topical)	31.6%	ON	YES-GENERIC			
RETIN-A MICRO (Topical)	7.4%	ON	YES			
NUOX (Topical)	0.0%	OFF	NO			
DIFFERIN (Topical)	8.3%	ON	YES			
EPIDUO (Topical)	0.1%	NR	NO			
TRETINOIN (Topical)	16.7%	ON	YES-GENERIC			
CLINDAGEL (Topical)	0.0%	OFF	NO			
INOVA (Topical)	0.0%	OFF	NO			
ZACLIR (Topical)	0.0%	OFF	NO			
ACZONE (Topical)	0.1%	OFF	NO			
BENZACLIN (Topical)	1.2%	OFF	NO			
ERYTHROMYCIN-BENZOYL PEROXIDE (Topical)	0.4%	OFF	NO-GENERIC			
SULFACETAMIDE/SULFUR (Topical)	0.9%	OFF	NO-GENERIC			
TAZORAC (Topical)	0.5%	OFF	NO			
ZIANA (Topical)	0.1%	OFF	NO			
AKNE-MYCIN (Topical)	0.0%	OFF	NO			
SULFACETAMIDE (Topical)	0.0%	OFF	NO-GENERIC			
ATRALIN (Topical)	0.0%	OFF	NO			
CLARIFOAM EF (Topical)	0.0%	OFF	NO			
EVOCLIN (Topical)	0.0%	OFF	NO			
ACANYA (Topical)	0.0%	NR	NO			
BENZEFOAM (Topical)	0.0%	NR	NO			
CLINDAMYCIN/BENZOYL PEROXIDE (Topical)	0.4%	OFF	NO-GENERIC			

17. ACNE AGENTS, TOPICAL (Acne)						
Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	State Modifications	Secretary Modifications
DUAC (Topical)	0.0%	OFF	NO			

- The Committee made a motion to accept staff recommendations.
 - Motion – Lawrence Fleming
 - Second – Brad Fedderly
 - All members were in favor of the motion.

18. IMPETIGO AGENTS, TOPICAL (Impetigo)						
Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	State Modifications	Secretary Modifications
MUPIROCIN OINTMENT (TOPICAL)	99.5%	ON	YES-GENERIC			
BACTROBAN CREAM (TOPICAL)	0.3%	OFF	NO			
ALTABAX (TOPICAL)	0.2%	OFF	NO			

- Discussion: This class will be expanded to include all topical infective products, including covered over-the-counter products.
- The Committee made a motion to accept staff recommendations.
 - Motion – James Boblin
 - Second – Steve Maike
 - All members were in favor of the motion.

19. ANTICOAGULANTS, INJECTABLE (Clot Prevention)						
Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	State Modifications	Secretary Modifications
FRAGMIN (SUBCUTANE.)	9.6%	ON	YES			
ARIXTRA (SUBCUTANE.)	4.0%	ON	YES			
LOVENOX (SUBCUTANE.)	86.4%	ON	YES			

- The Committee made a motion to accept staff recommendations.
 - Motion – Catherine Decker
 - Second – Ward Brown
 - All members were in favor of the motion.

20. ERYTHROPOEISIS STIMULATING PROTEINS (Treatment of Low Blood Levels)						
Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	State Modifications	Secretary Modifications
ARANESP (INJECTION)	38.9%	ON	YES			
PROCRIT (INJECTION)	56.7%	ON	YES			
EPOGEN (INJECTION)	4.4%	OFF	NO			

- The Committee made a motion to accept staff recommendations.
 - Motion – Michael Witkovsky
 - Second – Al Liegel
 - All members were in favor of the motion.

21. GROWTH HORMONE (Growth Deficiency)						
Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	State Modifications	Secretary Modifications
OMNITROPE (INJECTION)	0.00%	OFF	No			
TEV-TROPIN (INJECTION)	1.1%	OFF	No			
SAIZEN (INJECTION)	2.5%	OFF	No			
NUTROPIN AQ (INJECTION)	33.7%	ON	Yes			
NUTROPIN (INJECTION)	3.5%	ON	Yes			
NORDITROPIN (INJECTION)	23.3%	ON	Yes			
GENOTROPIN (INJECTION)	35.6%	ON	Yes			
SEROSTIM (INJECTION)	0.00%	OFF	No			
HUMATROPE (INJECTION)	0.3%	OFF	No			
ZORBTIVE (INJECTION)	0.00%	OFF	No			

- The Committee made a motion to accept staff recommendations.
 - Motion – Ron Diamond
 - Second – Pat Towers
 - All members were in favor of the motion.

22. HEPATITIS C AGENTS (Hepatitis C)						
Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	State Modifications	Secretary Modifications
RIBAVIRIN (ORAL)	46.4%	ON	Yes-Generic			

22. HEPATITIS C AGENTS (Hepatitis C)						
Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	State Modifications	Secretary Modifications
PEGASYS (SUBCUTANE.)	0.00%	ON	Yes			
PEG-INTRON REDIPEN (SUBCUTANE.)	21.1%	ON	Yes			
PEG-INTRON (SUBCUTANE.)	0.6%	ON	Yes			
INFERGEN (SUBCUTANE.)	2.3%	OFF	No			

- The Committee made a motion to accept staff recommendations.
 - Motion – Lawrence Fleming
 - Second – Pat Towers
 - All members were in favor of the motion.

23. MULTIPLE SCLEROSIS AGENTS (Multiple Sclerosis)						
Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	State Modifications	Secretary Modifications
BETASERON (SUBCUTANE.)	16.3%	ON	Yes			
COPAXONE (SUBCUTANE.)	40.6%	ON	Yes			
EXTAVIA (SUBCUTANE.)	0.1%	NR	No			
REBIF (SUBCUTANE.)	21.0%	ON	Yes			
AVONEX (INTRAMUSC.)	22.0%	ON	No			

- The Committee made a motion to accept staff recommendations, including grandfathering of current Avonex users.
 - Motion – James Boblin
 - Second – Ward Brown
 - All members were in favor of the motion.

24. BLADDER RELAXANTS PREPARATIONS (Overactive Bladder)						
Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	State Modifications	Secretary Modifications
OXYBUTYNIN (ORAL)	28.9%	ON	Yes-Generic			
SANCTURA (ORAL)	0.8%	OFF	No			
ENABLEX (ORAL)	3.5%	OFF	Yes			
VESICARE (ORAL)	27.6%	ON	Yes			
SANCTURA XR (ORAL)	0.7%	OFF	No			
GELNIQUE (TRANSDERM)	0.1%	NR	No			

24. BLADDER RELAXANTS PREPARATIONS (Overactive Bladder)						
Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	State Modifications	Secretary Modifications
TOVIAZ (ORAL)	0.2%	NR	No			
DETROL LA (ORAL)	3.2%	ON	No			
DETROL (ORAL)	0.5%	OFF	No			
OXYBUTYNIN ER (ORAL)	4.4%	OFF	No-Generic			
OXYTROL (TRANSDERM.)	0.1%	ON	No			

- The Committee made a motion to accept staff recommendations and include an age restriction for oxybutynin ER for children 18 years of age and younger.
 - Motion – James Boblin
 - Second – Ward Brown
 - All members were in favor of the motion.

25. BPH TREATMENTS (Enlargement of the Prostate)						
Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	State Modifications	Secretary Modifications
PROSCAR (ORAL)	4.5%	ON	Yes			
DOXAZOSIN (ORAL)	26.0%	ON	Yes-Generic			
TERAZOSIN (ORAL)	13.3%	ON	Yes-Generic			
UROXATRAL (ORAL)	3.1%	ON	Yes			
FLOMAX (ORAL)	40.3%	ON	Yes			
AVODART (ORAL)	10.4%	ON	No			
RAPAFLO (ORAL)	0.00%	NR	No			
FINASTERIDE (ORAL)	2.4%	OFF	No-Generic			
CARDURA XL (ORAL)	0.00%	OFF	No			

- The Committee made a motion to accept staff recommendations.
 - Motion – Lawrence Fleming
 - Second – Catherine Decker
 - All members were in favor of the motion.

26. HYPOGLYCEMICS, MEGLITINIDES (Type 2 Diabetes)						
Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	State Modifications	Secretary Modifications
PRANDIN (ORAL)	34.9%	ON	YES			
NATEGLINIDE (ORAL)	65.0%	ON	NO-GENERIC			

26. HYPOGLYCEMICS, MEGLITINIDES (Type 2 Diabetes)						
Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	State Modifications	Secretary Modifications
PRANDIMET (ORAL)	0.1%	NR	NO			

- The Committee made a motion to accept staff recommendations.
 - Motion – Al Liegel
 - Second – Ward Brown
 - All members were in favor of the motion.

27. HYPOGLYCEMICS, TZD (Type 2 Diabetes)						
Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	State Modifications	Secretary Modifications
ACTOS (ORAL)	74.3%	ON	YES			
AVANDIA (ORAL)	15.7%	ON	YES			
AVANDARYL (ORAL)	0.4%	ON	YES			
ACTOPLUS MET (ORAL)	4.6%	ON	YES			
DUETACT (ORAL)	0.4%	ON	YES			
AVANDAMET (ORAL)	4.5%	ON	YES			

- The Committee made a motion to accept staff recommendations.
 - Motion – Ron Diamond
 - Second – James Boblin
 - All members were in favor of the motion.

28. PHOSPHATE BINDERS (Removal of Phosphates in Kidney Disease)						
Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	State Modifications	Secretary Modifications
PHOSLO (ORAL)	28.0%	ON	Yes			
ELIPHOS (ORAL)	0.1%	OFF	No			
CALCIUM ACETATE (ORAL)	3.9%	OFF	No-Generic			
FOSRENOL (ORAL)	9.0%	ON	Yes			
RENAGEL (ORAL)	52.4%	ON	Yes			
RENVELA (ORAL)	6.6%	OFF	No			

- The Committee made a motion to accept staff recommendations.
 - Motion – Michael Witkovsky
 - Second – James Boblin
 - All members were in favor of the motion.

29. ANTIHISTAMINES, MINIMALLY SEDATING (Allergies)						
Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	State Modifications	Secretary Modifications
LORATADINE/LORATADINE-D (ORAL)	54.5%	ON	Yes-Generic			
CETIRIZINESYRUP (ORAL)	4.3%	ON	Yes-Generic			
CETIRIZINE/CETIRIZINE-D (ORAL)	26.4%	ON	Yes-Generic			
CETIRIZINE SYRUP RX (ORAL)	0.1%	OFF	Yes-Generic			
LORATADINE SYRUP (ORAL)	6.9%	ON	Yes-Generic			
SEMPREX-D (ORAL)	0.00%	OFF	No			
CLARITIN CHEW OTC (ORAL)	0.00%	OFF	No			
CLARINEX SYRUP (ORAL)	0.00%	OFF	No			
FEXOFENADINE (ORAL)	5.1%	OFF	No-Generic			
ALLEGRA SYRUP (ORAL)	0.3%	OFF	No			
XYZAL (ORAL)	0.06%	OFF	No			
XYZAL SYRUP (ORAL)	0.1%	OFF	No			
CLARINEX/CLARINEX-D (ORAL)	0.5%	OFF	No			
ALLEGRA ODT (ORAL)	0.1%	OFF	No			
FEXOFENADINE-D 12-HOUR (ORAL)	0.00%	OFF	No-Generic			

- The Committee made a motion to accept staff recommendations.
 - Motion – Catherine Decker
 - Second – Ward Brown
 - All members were in favor of the motion.

30. OTIC ANTIBIOTICS (Ear Infections)						
Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	State Modifications	Secretary Modifications
OFLOXACIN (OTIC)	22.7%	ON	Yes-Generic			
NEOMYCIN/POLYMYXIN/HC (OTIC)	38.5%	NR	Yes-Generic			
COLY-MYCIN S (OTIC)	0.00%	NR	Yes			
CIPRO HC (OTIC)	0.3%	OFF	Yes			

30. OTIC ANTIBIOTICS (Ear Infections)						
Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	State Modifications	Secretary Modifications
CORTISPORIN-TC (OTIC)	0.2%	NR	No			
CIPRODEX (OTIC)	38.3%	ON	No			
CETRAXAL (OTIC)	0.00%	NR	No			

- The Committee made a motion to accept staff recommendations.
 - Motion – Lawrence Fleming
 - Second – Ward Brown
 - All members were in favor of the motion.

31. PAH AGENTS (Pulmonary Arterial Hypertension)						
Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	State Modifications	Secretary Modifications
REVATIO (ORAL)	72.6%	ON	Yes			
ADCIRCA (ORAL)	0.3%	NR	No			
LETAIRIS (ORAL)	4.4%	ON	Yes			
TRACLEER (ORAL)	20.9%	OFF	Yes			
VENTAVIS (INHALATION)	1.6%	NA	No			
TYVASO (INHALATION)	0.3%	NA	No			

- The Committee made a motion to accept staff recommendations.
 - Motion – James Boblin
 - Second – Ward Brown
 - All members were in favor of the motion.

32. COUGH AND COLD, NARCOTICS (Cough and Cold)						
Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	State Modifications	Secretary Modifications
CHLORPHENIRAMINE/PE/ DIHYDROCODEINE		YES	YES			
PE/ PROMETHAZINE/ CODEINE		YES	YES			
PSE/ CHLORPHENIRAMINE/ DIHYDROCODEINE		YES	YES			
GUAIFENESIN- CODEINE		YES	YES			
GUAIFENESIN/PSE/ DIHYDROCODEINE		YES	YES			

32. COUGH AND COLD, NARCOTICS (Cough and Cold)						
Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	State Modifications	Secretary Modifications
PROMETHAZINE/ CODEINE		YES	YES			
BROMPHENIRAMINE/ PSE/ DIHYDROCODEINE		YES	YES			
BROMPHENIRAMINE/ PE/ DIHYDROCODEINE		YES	YES			
BROMPHENIRAMINE/ PSE/ CODEINE		YES	YES			
PE/ CODEINE		NO	NO			
PYRILAMINE MALEATE/ PE/ CODEINE		NO	NO			
PSE/ CODEINE		NO	NO			
PE/ DIHYDROCODEINE		NO	NO			
PE/ GUAIFENESIN/ CODEINE		NO	NO			
PSE/ GUAIFENESIN/ CODEINE		NO	NO			
BROMPHENIRAMINE/ CODEINE		NO	NO			
HYDROCODONE/ HOMATROPINE		NO	NO			
DIPHENHYDRAMINE/ PE/ CODEINE		NO	NO			
GUAIFENESIN/ DIHYDROCODEINE		NO	NO			
DEXCHLORPHENIRAMINE/ PE/ CODEINE		NO	NO			
PYRILAMINE MALEATE/ CODEINE		NO	NO			
CHLORPHENIRAMINE/ CODEINE		NO	NO			
TUSSIONEX		NO	NO			

- The Committee made a motion to accept staff recommendations.
 - Motion – Pat Towers
 - Second – James Boblin
 - The vote was 10 members in favor of the motion with one abstention.

Ron Diamond made a motion to adjourn the meeting and James Boblin seconded it. All members were in favor of the motion.

The next meeting will be scheduled for August 11 or August 18, 2010.

Thank you, Committee, for your time.